#TrialUpdate
LightNews LightNews
vjhemonc.bsky.social
#ASH24 | It was great to interview Vaishali Sanchorawala, who presented the updated results of the ANDROMEDA trial of dara + CyBorD vs CyBorD alone in AL #Amyloidosis.

Watch here:
👉 https://buff.ly/4glJhBr 👈

#HemOnc #ImmunoOnc #CTSM #TrialUpdate @ash.hematology.org
February 1, 2025 at 5:00 PM
vjoncology.bsky.social
🎥 Xiaoqian Nie, PhD, reports Phase I data:

➡️Erythrocyte–antibody conjugates show stronger antitumor activity & better safety vs PD-1 antibodies in checkpoint-refractory cancers. Promising novel IO strategy

🔗 buff.ly/cD7UDXr

@ascocancer.bsky.social #ASCO25 #Oncology #ImmunoOnc #CTSM #TrialUpdate
Evaluating erythrocyte-antibody conjugates in solid tumors - VJOncology
Xiaoqian Nie, PhD, Westlake University, Hangzhou, China, shares results of a Phase I trial (NCT06026605) investigating erythrocyte-antibody conjugates in cancers...
buff.ly
September 14, 2025 at 8:01 AM
vjhemonc.bsky.social
#18ICML | Neil Berinstein of @sunnybrookhsc.bsky.social shares updates from the BRAWM trial, which is evaluating the combination of bendamustine, rituximab, & acalabrutinib in Waldenström’s macroglobulinemia:

🎥 buff.ly/svYBGt2

#LYMsm #Lymphoma #RareDisease #HemOnc #ImmunoOnc #CTSM #TrialUpdate
August 7, 2025 at 9:01 AM
vjhemonc.bsky.social
It's always a pleasure to catch up with Jennifer Woyach!😊

At #ASH24, Dr Woyach gave an update on the Phase I trial of rocbrutinib, a novel BTKi, for the treatment of CLL:

👉 buff.ly/3DNNhx5 👈

#CLLsm #Leusm #TrialUpdate #MedSky #BloodSky #HemeSky #HemeOnc @ash-hematology.bsky.social
January 15, 2025 at 10:24 AM
vjhemonc.bsky.social
Hear updates from the BP41072 trial investigating glofitamab plus englumafusp alfa in R/R B-NHL from Martin Hutchings.🩸

Click here:
👉https://buff.ly/4fGhMSJ

#LYMsm #ASH24 #NonHodgkinLymphoma #ImmunoOnc #TrialUpdate #CTSM @ash-hematology.bsky.social #Hematology #BloodSky #HemeSky #HemeOnc
January 4, 2025 at 10:00 AM
vjhemonc.bsky.social
The trial of INCA33989, a mutCALR-specific monoclonal antibody, in #EssentialThrombocythemia generated plenty of excitement at the #EHA2025 meeting last week!🩸

Hear the details from John Mascarenhas:

👉 buff.ly/DyV3HNd 👈

#MPNsm #TrialUpdate #CTSM #BloodSky #HemeSky #ImmunoOnc #MedSky
June 17, 2025 at 4:02 PM
vjhemonc.bsky.social
Is a combination of isatuximab-bortezomib-lenalidomide feasible in elderly patients with #Myeloma?

Hear updates from the REST study in our interview w/ Fredrik Schjesvold at #ASH24:
👉 https://buff.ly/4ggEB0y 👈

#HemeSky #HemeOnc #MMSM #TrialUpdate #CTSM #ImmunoOnc @ash-hematology.bsky.social
December 16, 2024 at 2:30 PM
vjneurology.bsky.social
The Phase IV PEARL study assessed the real-world effectiveness of fremanezumab for the preventive treatment of #migraine. 🧠

Hear the findings in our recent interview with Messoud Ashina:

👉 buff.ly/QJ7ARiC 👈

#Neuroscience #Neurology #EAN2025 #CTSM #TrialUpdate
August 14, 2025 at 11:03 AM
vjhemonc.bsky.social
At #COMy2025, Sosana Delimpasi presented the findings of a subgroup analysis of the BOSTON trial, which assessed the feasibility of selinexor dose reduction in patients with len-refractory #MultipleMyeloma receiving the SVD regimen:

👉 buff.ly/j2nFgUq 👈

#MMSM #CTSM #TrialUpdate #ImmunoOnc
May 29, 2025 at 11:01 AM
vjhemonc.bsky.social
Have you had a chance to read our comprehensive feature article on moving beyond JAK inhibitor monotherapy in #myelofibrosis?🩸

Delve into the treatment options being explored and hear exclusive expert insights:

📖 👉 buff.ly/MN0SXef

#MPNsm #CTSM #TrialUpdate #HemOnc
April 24, 2025 at 3:04 PM
vjoncology.bsky.social
At #ESMO25, Dr Llombart Cussac presents #EMPRESS trial results: giredestrant led to greater Ki67 reduction and stronger ER/PR decreases vs tamoxifen in premenopausal ER+/HER2- early #BreastCancer.

🎥 Watch: buff.ly/vLWxnoe

#BCSM #CTSM #TrialUpdate #Oncology
EMPRESS: giredestrant vs tamoxifen in ER+/HER2- early breast cancer - VJOncology
Antonio Llombart Cussac, MD, PhD, Arnau de Vilanova Hospital of Valencia, Valencia, Spain, discusses results from the Phase II EMPRESS...
buff.ly
November 10, 2025 at 3:54 PM
vjhemonc.bsky.social
Want to hear about the updated efficacy and safety of HBI0101, an anti-BCMA CAR-T, for treating R/R AL #Amyloidosis?

Watch our interview w/ Eyal Lebel from #ASH24 here:

👉 https://buff.ly/41KYBUJ

#TrialUpdate #CTSM #CARTCell #ImmunoOnc #HemOnc #BloodSky #HemeSky @ash-hematology.bsky.social
December 26, 2024 at 12:00 PM
vjhemonc.bsky.social
Thank you to Hans Lee of @mdanderson.bsky.social for stopping by at #SOHO2025 last week to share the promising results of the first-in-human Phase I study of JNJ-5322, a novel trispecific antibody, in R/R #myeloma.🩸

Watch the interview here:
👉 buff.ly/iPVlfS4 👈

#ImmunoOnc #CTSM #TrialUpdate #MMSM
September 12, 2025 at 1:31 PM
vjoncology.bsky.social
⭐ Jason Mouabbi, MD, of @mdanderson.bsky.social, shares an overview of key studies in breast cancer presented at #ASCO25:

🎥 buff.ly/0IeuM2Z

@ascocancer.bsky.social #BCSM #BreastCancer #CTSM #TrialUpdate #ImmunoOnc
ASCO 2025 highlights in breast cancer: ASCENT-04, SERENA-6, and more - VJOncology
Jason Mouabbi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, gives an overview of key studies in...
buff.ly
October 6, 2025 at 2:54 PM
handle.invalid
CNBC's Kate Rooney updates 'Power Lunch' audience about the Sam Bankman-Fried trial. Headline news: 'Sam Bankman-Fried to give testimony without jury'. #SamBankmanFried #TrialUpdate According to CNBC Television.
Sam Bankman-Fried to give testimony without jury
CNBC's Kate Rooney updates 'Power Lunch' audience about the Sam Bankman-Fried trial. Headline news: 'Sam Bankman-Fried to give testimony without jury'. #SamBankmanFried #TrialUpdate According to CNBC Television.
cryptonews.blue
October 26, 2023 at 7:20 PM
vjhemonc.bsky.social
At #EHA2025, Matthew Ku presented initial results of a Phase Ib study investigating JNJ-90014496, a bispecific #CARTCell therapy targeting CD19 & CD20, in CAR-T naïve pts with R/R large B-cell #lymphoma:

🎥 buff.ly/fBNjeMN

#LYMsm #TrialUpdate #CTSM #HemOnc #BloodSky #HemeSky #MedSky
July 14, 2025 at 9:02 AM
vjhemonc.bsky.social
It was a pleasure to catch up with @chancheah.bsky.social‬ at #EHA2025 to hear the updated Phase I results of sonrotoclax plus zanubrutinib in patients with R/R CLL/SLL.🩸

Watch the interview here:
👉 buff.ly/TYQfq4h 👈

#CLLsm #Leusm #LYMsm #CTSM #TrialUpdate #BloodSky #HemeSky #MedSky #HemOnc
June 25, 2025 at 10:02 AM
vjhemonc.bsky.social
Want to hear findings from the EPCORE NHL-2 trial evaluating epcoritamab plus intensive chemo for patients with R/R #DLBCL eligible for autoSCT?

Watch our interview with Marek Trněný of @charlesuni.cuni.cz from #SOHO2025:

👉 buff.ly/GHh6dYG 👈

#LYMsm #CTSM #TrialUpdate #BloodSky #HemeSky #MedSky
October 20, 2025 at 5:28 PM
vjoncology.bsky.social
🎥Stefanie Zschaebitz, MD, of @uniheidelberg.bsky.social shares TALAPRO-2 gene-level data in mCRPC: talazoparib + enzalutamide improved rPFS/OS in HRR-deficient tumors:

🔗 ow.ly/ook950WiqkB

@ascocancer.bsky.social #ASCO25 #PCsm #mCRPC #HRR #CTSM #TrialUpdate
TALAPRO-2: efficacy of talazoparib & enzalutamide by HRR gene subgroup in mCRPC - VJOncology
Stefanie Zschaebitz, MD, Heidelberg University Hospital, Heidelberg, Germany, discusses gene-level outcomes from the HRR-deficient cohort of the TALAPRO-2 trial (NCT03395197),...
ow.ly
July 11, 2025 at 4:04 PM
vjhemonc.bsky.social
At #IMS25, we caught up with Xavier Leleu of to hear about the Phase III IRAKLIA trial investigating isatuximab administered subcutaneously via an on-body injector versus intravenously in patients with R/R #MultipleMyeloma:

🎥 buff.ly/T67u8VR

#MMsm #Myeloma #TrialUpdate @myeloma-society.bsky.social
September 30, 2025 at 9:01 AM
vjoncology.bsky.social
⭐ Fabrice André, MD, PhD, shares KEYNOTE-756 results:

➡️ Adding pembrolizumab to neoadjuvant chemo improved pCR in high-risk ER+/HER2- breast cancer. EFS data pending...

🎥 buff.ly/0R25Yjb

#ESMOBreast25 #BreastCancer #BCSM #CTSM #TrialUpdate #ImmunoOnc
KEYNOTE-756: pembrolizumab & neoadjuvant chemotherapy in ER+/HER2- breast cancer - VJOncology
Fabrice André, MD, PhD, Gustave Roussy, Villejuif, France, discusses the Phase III KEYNOTE-756 study (NCT03725059) of pembrolizumab with neoadjuvant chemotherapy...
buff.ly
October 4, 2025 at 2:54 PM
vjhemonc.bsky.social
It was great to catch up with Juan Alderuccio at #18ICML to hear the results from the LOTIS-7 trial of loncastuximab tesirine plus glofitamab in patients with R/R NHL.

Watch the interview here:
👉 buff.ly/n2ldbrC 👈

#LYMsm #Lymphoma #CTSM #TrialUpdate #ImmunoOnc #HemOnc #DLBCL
buff.ly
September 2, 2025 at 8:29 AM
journosnews.com
Diddy’s Legal Setback: Request to Postpone Trial Rejected
#Diddy #SeanCombs #SexTraffickingTrial #FederalTrial #JurySelection #CourtRuling #LegalNews #NewYorkCourt #DiddyTrial #SexTrafficking #CassieVentura #TrialUpdate #CriminalDefense #RapeCharges #ProstitutionCharges #FreakOffs #Racketeering
Diddy’s Request to Delay Sex-Trafficking Trial Denied
Judge Denies Diddy’s Request to Delay Sex-Trafficking Trial, Jury Selection Set for May 5 A federal judge in New York
journosnews.com
April 19, 2025 at 12:39 AM
dlunited.bsky.social
📣 #TrialUpdate! We're celebrating DLU Legal Director Cynthia Rice & staff attorney Aviance Brown, who with co-counsel just spent the week in trial in Sacramento, California, seeking to force changes to address the Sacramento Police Department’s discriminatory & violent policies and practices.

1/3
A white woman with short grey hair wearing a grey and black suit, and a Black woman with long hair wearing a navy suit and gold blouse, standing on a stone floor in the Sacramento federal courthouse. They are both smiling and resting their hands on a short pillar engraved with the words, "Cancel the afternoons, evenings, mornings, the days to come, until the fires fall to ash, the fog clears and we can see where we really stand." A white woman with short grey hair wearing a grey and black suit, and a Black woman with long hair wearing a navy suit and gold blouse, standing on a stone floor in the Sacramento federal courthouse. They are both laughing and facing each other as if in joyful conversation.
April 4, 2025 at 6:09 PM
vjhemonc.bsky.social
At #EHA2025, we had the opportunity to catch up with Amir Fathi to hear the promising results of the Phase Ib/II KOMET-001 study of ziftomenib in R/R NPM1-mutant AML.

Check out the interview here:

👉 buff.ly/IlVeBKE

#AMLsm #Leusm #CTSM #TrialUpdate #BloodSky #HemeSky #MedSky
July 21, 2025 at 9:01 AM